Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 2125   Home Print this page  Email this page Small font size Default font size Increase font size


 
  Table of Contents    
EDITORIAL
Year : 2012  |  Volume : 29  |  Issue : 1  |  Page : 2-3  

Surgery in limited-disease small-cell lung cancer


Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India

Date of Web Publication28-Jan-2012

Correspondence Address:
Parvaiz A Koul
Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-2113.92345

Rights and Permissions

How to cite this article:
Koul PA. Surgery in limited-disease small-cell lung cancer. Lung India 2012;29:2-3

How to cite this URL:
Koul PA. Surgery in limited-disease small-cell lung cancer. Lung India [serial online] 2012 [cited 2019 Sep 20];29:2-3. Available from: http://www.lungindia.com/text.asp?2012/29/1/2/92345

Small cell carcinoma of lung (SCLC) constitutes about 15% of the lung cancers and due to its clinical and biologic characteristics is considered distinct from other lung carcinomas, collectively termed as non-small-cell lung carcinomas (NSCLC). SCLC exhibits an aggressive behavior that is characterized by rapid growth, early metastasis to distant sites, and exquisite sensitivity to chemotherapeutic agents and radiation. Currently combined chemotherapy and thoracic radiation therapy is the standard treatment for patients with limited-stage disease SCLC (LD): the combination of platinum and etoposide with thoracic radiation therapy being the most widely used regimen with clinical trials consistently having achieved median survivals of 18 to 24 months and 40% to 50% 2-year survival rates with less than a 3% treatment-related mortality. [1],[2],[3]

Generally unresectable at presentation due to local spread or dissemination, the role of surgery in SCLC, especially in the early stages, has remained a subject of considerable interest in recent years. In this issue of the journal, Arturo and Daniel present successful 2-year follow up of a patient with LD-SCLC who presented as a solitary pulmonary nodule and was managed with multimodality treatment including surgical resection. The authors recommend that surgical resection should be considered in the management of patients with LD-SCLC.

Although surgery was initially regarded as the treatment of choice for all types of lung cancer, it was abandoned for SCLC almost 30 years ago after the results of the Medical Research Council randomized trial revealed a significant survival difference between surgery and radiotherapy, a 4-year survival of 3% and 7%, respectively, and a 5-year survival of 5% in the radiotherapy arm. [4] After this study radiation therapy became the favored treatment for SCLC till the introduction and advancements in chemotherapy. After the introduction of TNM classification, investigators proposed that surgery was postulated to be indicated in LD-SCLC, particularly stage T1, N0, with 5-year survival rates of as high as 57.1% for stage 1 disease. [5],[6],[7] Ankaru and Waddell, [8] reviewed the rationale of surgery in SCLC and supported its utilization arguing that with current chemoradiotherapy protocols demonstrating local failure rates up to 50%, [9] surgical resection for T1-2, N0, M0 SCLC, could offer better local control of the disease compared to chemotherapy alone. Further, surgical resection after induction chemoradiotherapy demonstrated a control of local relapse in almost 100% of the patients and 5 and 10 year survival rates for patients with stage IIB to IIA were 39% and 35%, respectively, for all patients (resected or not) and 44% and 41% for patients treated with a trimodality approach including adjuvant surgery. [10] They also argued that the final histology of SCLC might reveal a component of NSCLC in 11-25% cases [11] and other histological subtypes might be misdiagnosed as SCLC prior to surgical resection, [8],[12] and that it would be more logical to offer surgery in mixed or combined small-cell tumors. Salvage surgery could also be preferable to second line chemotherapy in cases of SCLC where after an initial response to chemoradiotherapy, a chemotherapy resistant tumor or a local recurrence of the disease is incident or in patients with mixed histology. [8]

Although no prospective randomized control trials comparing combined adjuvant surgery to chemotherapy or chemoradiotherapy alone are reported, accumulated data have shown that surgery can contribute to both prognosis and local recurrence control. Granetzny et al, [13] in a retrospective trial studied the effect of surgery in a trimodality treatment in 95 patients with SCLC and reported that patients with stage I and II SCLC can be treated with promising results using a combination of primary surgery and adjuvant chemotherapy as well as thoracic and cranial irradiation. Reviewing 2442 patients with SCLC in Norway, 38 of whom underwent surgical resection in conjunction with the routine therapy, Rostad et al, [14] concluded that more patients with peripherally located tumors stage 1A and 1B should have been referred for surgery because the 5-year survival rate for stage-1 patients improved from 11.3% for conventional treatment to 44.9% with the addition of surgery. Other investigators [15],[16],[17] too have supported adjuvant surgery in early stage SCLC whereas in stages II and III it is proposed to be planned in a multidisciplinary basis, in the context of controlled trials. [15] In a report by investigators from the Imperial College, UK, lung resection and mediastinal lymph node dissection used as primary therapy for SCLC in either pure (73%) or in mixed histological types was associated with a surprisingly 5- year survival for the total cohort of stage I-III patients of 52% independently of the tumor's T, N, and UICC stage. [17] This report strongly suggested that selected patients with SCLC, even in more advanced stage disease may benefit from surgery if complete tumor resection is achieved. In yet another recent study, Yu et al, [18] reported a 5-year survival of 50.3% amongst 205 patients with stage 1 SCLC who underwent surgical resection (lobectomy only) and they concluded that surgery without radiotherapy appears to offer reasonable survival outcomes in patients with stage I SCLC.

Hence, despite lack of randomized trials time has come to accept that surgery has to play an important role in management of LD-SCLC, either as a primary treatment or as adjuvant therapy. Thus, patients with early-stage SCLC (T1-2 N0 and perhaps even stage II) or "very limited" (to use a phrase coined by the University of Toronto Thoracic Oncology Group) [12] may benefit from a combined modality approach that includes surgery. In stage II disease induction concurrent chemotherapy and radiotherapy should be given and radical resection should follow with intent to curative therapy only if there has been a definite initial response to the induction treatment. In stage IIIA, if adjuvant surgery is planned, a mediastinoscopy should always precede the surgical treatment. If mediastinal clearance has not been achieved it is doubtable that surgery will contribute to survival. Finally surgery should be considered in mixed tumors, as a salvage therapy or in the rare cases of a second NSCLC tumor. [19] All investigators have emphasized the importance of precise staging for careful selection of patients. Pathologists also need to be cautious to rule out any coexisting NSCLC component or a mixed tumor. If SCLC is revealed at frozen section analysis in the operating room, and frozen sections suggest the absence of hilar or mediastinal nodal involvement, a radical resection has been proposed, which may be combined with lymph node dissection in N2 disease. [19] If the procedure can easily be tolerated. The case by Arturo and Daniel et al, [20] is another admonition that must prompt physicians dealing with lung cancer to strongly consider surgery in patients with LD-SCLC, mostly in tandem with other modalities of management. Since very few patients fall into this category, a randomized international collaborative study is the need of the hour to carve recommendations based on robust statistical numbers.

 
   References Top

1.McCracken JD, Janaki LM, Crowley JJ, Taylor SA, Giri PG, Weiss GB, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group Study. J Clin Oncol 1990;8:892-8.   Back to cited text no. 1
    
2.Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60.  Back to cited text no. 2
    
3.Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996;14:806-13.  Back to cited text no. 3
    
4.Fox W, Scadding JG. Medical research council comparative trial of surgery and radiotherapy for primary treatment of small cell or oat-cell carcinoma of the bronchus Ten year follow up. Lancet 1973;2:63-5.  Back to cited text no. 4
    
5.Shields TW, Higgins GA Jr, Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982;84:481-8.  Back to cited text no. 5
    
6.Shepherd FA, Ginsberg RJ, Evans WK, Feld R, Cooper JD, Ilves R, et al. Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. J Thorac Cardiovasc Surg 1983;86:498-506.  Back to cited text no. 6
    
7.Shah SS, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment of SCLC. Ann Thorac Surg 1992;54:498-501.   Back to cited text no. 7
    
8.Anraku M, Waddell TK. Surgery for small-cell lung cancer. Semin Thorac Cardiovasc Surg 2006;18:211-6.  Back to cited text no. 8
    
9.Turrisi AT 3 rd , Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited SCLC treated concurrently with cisplatin and etoposside. N Engl J Med 1999;340:265-71.  Back to cited text no. 9
    
10.Eberhardt W, Korfee S. New approaches for small-cell lung cancer: Local treatments. Cancer Control 2003;10:289-96.  Back to cited text no. 10
    
11.Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin Oncol 2006;24:70-6.  Back to cited text no. 11
    
12.Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Surg 1991;101:385-93.  Back to cited text no. 12
    
13.Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, et al. Surgery in the trimodality treatment of small cell lung cancer. Eur J Cardiothorac Surg 2006;30:212-6.  Back to cited text no. 13
    
14.Rostad H, Naalsund A, Jacobsen R, Strand TE, Scott H, Heyerdahl Strom E, et al. Small cell lung cancer in Norway Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg 2004;26:782-6.  Back to cited text no. 14
    
15.Leo F, Pastorino U. Surgery in small cell lung carcinoma. Where is the rationale? Semin Surg Oncol 2003;21:176-81.  Back to cited text no. 15
    
16.Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin 2004;14:271-81.  Back to cited text no. 16
    
17.Lim E, Belcher E, Yap YK, Nicholson A, Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: Time to reevaluate. J Thorac Oncol 2008;3:1267-71.  Back to cited text no. 17
    
18.Yu JB, Decker RH, Detterbeck F, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010;5:215-9.  Back to cited text no. 18
    
19.Kolestis EN, Prokakis C, Karanikolas M, Apostolakis E, Douglas D. Current role of surgery in small cell carcinoma. J Cardiothoracic Surg 2009;4:30.  Back to cited text no. 19
    
20.Cortés-Télles A, Daniel M. Relevance of an incidental chest finding. Lung India 2012;29:50-2.  Back to cited text no. 20
    



This article has been cited by
1 A Case of Small-cell Lung Cancer with a Peculiar Progressive Pattern
Takatoshi Abe,Isao Matsumoto,Makoto Oda,Kazuo Kasahara,Takashi Sone,Go Watanabe
Haigan. 2013; 53(2): 127
[Pubmed] | [DOI]
2 Comments: Other considerations about surgery in lung cancer
Ghanei, M. and Saburi, A. and Akhavan-Moghadam, J.
Lung India. 2012; 29(3): 303
[Pubmed]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1668    
    Printed81    
    Emailed0    
    PDF Downloaded409    
    Comments [Add]    
    Cited by others 2    

Recommend this journal